ATE391134T1 - Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung - Google Patents

Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung

Info

Publication number: ATE391134T1
Authority: AT; Austria
Prior art keywords: oligonucleotides; oligonucleotide; thiophosphoramidates; synthesis; inventive
Prior art date: 1999-09-10

Application number

AT00961689T

Other languages

English (en)

Inventor

Sergei Gryaznov

Krisztina Pongracz

Tracy Matray

Original Assignee

Geron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-10

Filing date

2000-09-08

Publication date

2008-04-15

2000-09-08 Application filed by Geron Corp filed Critical Geron Corp

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE391134T1 publication Critical patent/ATE391134T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 5
230000015572 biosynthetic process Effects 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
230000004570 RNA-binding Effects 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000008298 phosphoramidates Chemical class 0.000 abstract 1
230000002194 synthesizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT00961689T 1999-09-10 2000-09-08 Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung ATE391134T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15320199P	1999-09-10	1999-09-10
US16044499P	1999-10-19	1999-10-19

Publications (1)

Publication Number	Publication Date
ATE391134T1 true ATE391134T1 (de)	2008-04-15

Family

ID=26850281

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00961689T ATE391134T1 (de)	1999-09-10	2000-09-08	Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung

Country Status (17)

Country	Link
US (5)	US6608036B1 (de)
EP (2)	EP1992634A1 (de)
JP (2)	JP4267233B2 (de)
KR (2)	KR100858465B1 (de)
CN (1)	CN1317291C (de)
AT (1)	ATE391134T1 (de)
AU (2)	AU767646B2 (de)
CA (1)	CA2382521C (de)
CY (1)	CY1108158T1 (de)
DE (1)	DE60038495T2 (de)
DK (1)	DK1210357T3 (de)
ES (1)	ES2302701T3 (de)
HK (1)	HK1049339B (de)
IL (2)	IL148304A0 (de)
MX (1)	MXPA02002577A (de)
PT (1)	PT1210357E (de)
WO (1)	WO2001018015A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5523389A (en) *	1992-09-29	1996-06-04	Isis Pharmaceuticals, Inc.	Inhibitors of human immunodeficiency virus
US20030032610A1 (en) *	1996-06-03	2003-02-13	Gilchrest Barbara A.	Method to inhibit cell growth using oligonucleotides
WO2000047599A1 (en)	1999-02-12	2000-08-17	Sankyo Company, Limited	Novel nucleosides and oligonucleotide analogues
KR100858465B1 (ko) *	1999-09-10	2008-09-16	제론 코포레이션	올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도
AU2001251115A1 (en)	2000-03-31	2001-10-15	Trustees Of Boston University	Use of locally applied dna fragments
AU2003244338C1 (en) *	2001-03-23	2008-07-24	Geron Corporation	Oligonucleotide conjugates
US7563618B2 (en)	2001-03-23	2009-07-21	Geron Corporation	Oligonucleotide conjugates
EP1379689B1 (de) *	2001-03-23	2012-09-26	Geron Corporation	Oligonukleotidkonjugate
DE10159904A1 (de) *	2001-12-06	2003-07-03	Adnagen Ag	Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
WO2004037842A1 (ja) *	2002-10-23	2004-05-06	Sankyo Company, Limited	糖部ｓ型配座の新規人工核酸
HUE043168T2 (hu)	2003-06-23	2019-08-28	Telomerase Activation Sciences Inc	Készítmények telomeráz-aktivitás fokozására
US9248088B2 (en)	2003-06-25	2016-02-02	Telomerase Activation Sciences, Inc.	Compositions and methods for skin conditioning
JP4690324B2 (ja)	2003-09-09	2011-06-01	ジェロン・コーポレーション	テロメラーゼ阻害のための改変オリゴヌクレオチド
WO2005047506A1 (en)	2003-11-04	2005-05-26	Geron Corporation	Rna amidates and thioamidates for rnai
TW200540180A (en) *	2004-05-28	2005-12-16	Sankyo Co	Telomerase inhibitor ena oligonucleotide
SI3296312T1 (sl)	2004-07-02	2021-08-31	Geron Corporation	Sinteza zaščitenih 3'-amino 5'-fosforamiditnih nukleozidnih monomerov
EP1828217A2 (de) *	2004-12-16	2007-09-05	Febit Biotech GmbH	Polymeraseunabhängige analyse der sequenz von polynukleotiden
WO2006113426A2 (en) *	2005-04-15	2006-10-26	Geron Corporation	Cancer treatment by combined inhibition of telomerase and tubulin activities
US8153604B2 (en) *	2006-04-24	2012-04-10	Geron Corporation	CNS-tumor treatment method and composition
SI2101789T1 (sl)	2006-10-30	2015-04-30	Geron Corporation	Kombinirani inhibitor telomeraze in gemcitabin za zdravljenje raka
US8785409B2 (en)	2007-01-30	2014-07-22	Geron Corporation	Compounds having anti-adhesive effects on cancer cells
US8011527B2 (en) *	2007-08-10	2011-09-06	Rexam Beverage Can Company	Can end with countersink
HRP20160067T1 (hr)	2008-10-17	2016-03-25	Geron Corp	Postupak za utvrđivanje osjetljivosti bolesnika na liječenje inhibicijom telomeraze
US8759318B2 (en) *	2009-01-09	2014-06-24	Inhibitex, Inc.	Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
ES2874774T3 (es)	2011-12-22	2021-11-05	Geron Corp	Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
EP2830991A1 (de)	2012-03-26	2015-02-04	President and Fellows of Harvard College	Lipidbeschichtete nucleinsäurenanostrukturen von definierter form
HK1214293A1 (zh) *	2012-10-26	2016-07-22	Geron Corporation	C-myc反义寡核苷酸和利用其治疗细胞增殖性疾病的方法
US9228189B2 (en)	2012-10-26	2016-01-05	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US9200327B2 (en)	2012-11-30	2015-12-01	Geron Corporation	Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US10138507B2 (en)	2013-03-15	2018-11-27	Modernatx, Inc.	Manufacturing methods for production of RNA transcripts
US10077439B2 (en)	2013-03-15	2018-09-18	Modernatx, Inc.	Removal of DNA fragments in mRNA production process
EP2983804A4 (de)	2013-03-15	2017-03-01	Moderna Therapeutics, Inc.	Ionenaustauschreinigung von mrna
WO2014152031A1 (en)	2013-03-15	2014-09-25	Moderna Therapeutics, Inc.	Ribonucleic acid purification
CN103382212B (zh) *	2013-07-06	2016-08-31	中国科学院成都生物研究所	5′位改性嘌呤霉素化合物及其制备方法和用途
RS62529B1 (sr)	2013-07-11	2021-11-30	Modernatx Inc	Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
EP3052512A4 (de)	2013-09-30	2017-02-22	Geron Corporation	Phosphorodiamidat-rückgratverbindung für oligonukleotide
EP3052511A4 (de)	2013-10-02	2017-05-31	Moderna Therapeutics, Inc.	Polynukleotidmoleküle und verwendungen davon
EP3065722A4 (de) *	2013-11-08	2017-11-15	Dana-Farber Cancer Institute, Inc.	Nukleinsäurenanostrukturen zur in-vivo-wirkstoffverabreichung
CN106456694B (zh)	2013-12-20	2020-06-30	通用医疗公司	与循环肿瘤细胞相关的方法和测定法
JOP20200257A1 (ar) *	2014-05-01	2017-06-16	Geron Corp	تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
EP3157573A4 (de)	2014-06-19	2018-02-21	Moderna Therapeutics, Inc.	Alternative nukleinsäuremoleküle und verwendungen davon
US10407683B2 (en)	2014-07-16	2019-09-10	Modernatx, Inc.	Circular polynucleotides
EP3169693B1 (de) *	2014-07-16	2022-03-09	ModernaTX, Inc.	Chimäre polynukleotide
EA035885B1 (ru) *	2015-04-23	2020-08-27	Джерон Корпорейшн	Способы получения полинуклеотидов с использованием композиций солей поливалентных катионов
DK3350333T3 (da)	2015-09-17	2022-01-31	Modernatx Inc	Polynukleotider, der indeholder en stabiliserende haleregion
US11434486B2 (en)	2015-09-17	2022-09-06	Modernatx, Inc.	Polynucleotides containing a morpholino linker
WO2017223176A1 (en)	2016-06-24	2017-12-28	Modernatx, Inc.	Methods and apparatus for filtration
EP3318276A1 (de)	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Zusammensetzungen aus einem telomerase-hemmer und einem bcl-2-hemmer zur behandlung von blutkrebs
IL315071A (en) *	2016-09-14	2024-10-01	Janssen Biopharma Llc	Modified oligonucleotides and pharmaceutical compositions
CN116804031A (zh) *	2016-09-20	2023-09-26	科罗拉多州立大学董事会法人团体	使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体
TW201831684A (zh) *	2016-11-11	2018-09-01	美商艾洛斯生物製藥公司	用於ｃｃｃＤＮＡ之寡核苷酸標靶策略
JPWO2018221735A1 (ja) *	2017-06-02	2020-05-21	富田製薬株式会社	新規オリゴヌクレオチド
BR112020000410A2 (pt)	2017-07-10	2020-07-14	Geron Corporation	processo aprimorado para preparar imetelstat
EP3658156B1 (de)	2017-07-28	2026-03-25	Geron Corporation	Telomerase hemmer zur behandlung eines myelodysplastischen syndroms
MX2020002882A (es) *	2017-09-14	2020-10-05	Janssen Biopharma Inc	Fosforamiditas de nucleósido modificado.
SG11202008895WA (en)	2018-03-13	2020-10-29	Janssen Pharmaceutica Nv	Modified oligonucleotides for use in treatment of tauopathies
JP2021525507A (ja) *	2018-05-25	2021-09-27	ニューヨークインスティチュートオブテクノロジーＮｅｗＹｏｒｋＩｎｓｔｉｔｕｔｅＯｆＴｅｃｈｎｏｌｏｇｙ	直接核酸配列決定方法
EP3818066B1 (de)	2018-07-05	2022-06-15	Agilent Technologies, Inc.	Doppelkupplungsverfahren zur oligonukleotidsynthese
UA130012C2 (uk)	2018-11-29	2025-10-15	Джерон Корпорейшн	Спосіб лікування мієлодиспластичного синдрому
WO2020210468A1 (en)	2019-04-10	2020-10-15	President And Fellows Of Harvard College	Nucleic acid nanostructures crosslinked with oligolysine
WO2021198958A1 (en)	2020-04-01	2021-10-07	Janssen Biopharma, Inc.	Nucleic acid polymers
CN118388567A (zh) *	2024-06-26	2024-07-26	广州表观生物科技有限公司	一种特异性靶向酪氨酸酶、制备方法及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4394448A (en)	1978-02-24	1983-07-19	Szoka Jr Francis C	Method of inserting DNA into living cells
US4647529A (en)	1984-06-01	1987-03-03	Rodland Karin D	Hybridization method of detecting nucleic acid sequences with probe containing thionucleotide
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5124246A (en)	1987-10-15	1992-06-23	Chiron Corporation	Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5109124A (en)	1988-06-01	1992-04-28	Biogen, Inc.	Nucleic acid probe linked to a label having a terminal cysteine
US5501959A (en)	1989-01-17	1996-03-26	Alamar Biosciences Laboratory, Inc.	Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en)	1989-06-07	1995-06-13	Affymax Technologies N.V.	Very large scale immobilized polymer synthesis
US5506212A (en)	1990-01-11	1996-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides with substantially chirally pure phosphorothioate linkages
IL99120A0 (en) *	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5412087A (en)	1992-04-24	1995-05-02	Affymax Technologies N.V.	Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US6017895A (en)	1992-02-10	2000-01-25	Genzyme Corporation	Oligonucleotides possessing zwitterionic moieties
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5645986A (en) *	1992-05-13	1997-07-08	Board Of Reagents, The University Of Texas System	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5654286A (en) *	1993-05-12	1997-08-05	Hostetler; Karl Y.	Nucleotides for topical treatment of psoriasis, and methods for using same
JPH09500378A (ja)	1993-07-02	1997-01-14	リンクスセラピューティクス，インコーポレイティド	枝分れされそして複雑に結合された高分子構造体の集中的合成
US5637684A (en)	1994-02-23	1997-06-10	Isis Pharmaceuticals, Inc.	Phosphoramidate and phosphorothioamidate oligomeric compounds
US5599922A (en)	1994-03-18	1997-02-04	Lynx Therapeutics, Inc.	Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en)	1994-03-18	1998-03-10	Lynx Therapeutics, Inc.	Oligodeoxyribonucleotide N3' P5' phosphoramidates
CZ274596A3 (en)	1994-03-18	1997-03-12	Lynx Therapeutics	Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization
US5776679A (en)	1994-07-07	1998-07-07	Geron Corporation	Assays for the DNA component of human telomerase
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
HUT78054A (hu)	1994-07-07	1999-07-28	Geron Corporation	Emlőseredetű telomeráz RNS-összetevője
US5972605A (en)	1994-07-07	1999-10-26	Geron Corporation	Assays for regulators of mammalian telomerase expression
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5643890A (en) *	1995-01-31	1997-07-01	The Board Of Regents Of The University Of Nebraska	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US6004939A (en)	1995-07-06	1999-12-21	Ctrc Research Foundation Board Of Regents	Methods for modulation and inhibition of telomerase
US5968506A (en) *	1995-08-04	1999-10-19	Geron Corporation	Purified telomerase
US5856096A (en) *	1995-09-20	1999-01-05	Ctrc Research Foundation	Rapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activities
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US5684143A (en)	1996-02-21	1997-11-04	Lynx Therapeutics, Inc.	Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
WO1997037891A1 (fr)	1996-04-05	1997-10-16	German Viktorovich Demidov	Unite motrice et de transport comportant un module energetique
US6015710A (en) *	1996-04-09	2000-01-18	The University Of Texas System	Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en)	1996-04-10	1997-10-29	Lynx Therapeutics, Inc.	Telomerase inhibitors
EP1736554B1 (de) *	1996-05-29	2013-10-09	Cornell Research Foundation, Inc.	Bestimmung von Unterschieden in der Nukleinsäuresequenz mittels einer Kombination von Ligasebestimmung und Polymerasekettenreaktion
EP0954585B1 (de)	1996-10-01	2009-11-25	Geron Corporation	Menschlicher telomerase reverse transcriptase promoter
US6093809A (en)	1996-10-01	2000-07-25	University Technology Corporation	Telomerase
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
DE19720151A1 (de) *	1997-05-02	1998-11-05	Max Delbrueck Centrum	Chimäre Oligonucleotide und ihre Verwendung
JPH11228451A (ja) *	1998-02-10	1999-08-24	Kureha Chem Ind Co Ltd	抗癌性増強医薬組成物
KR100858465B1 (ko) *	1999-09-10	2008-09-16	제론 코포레이션	올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도
WO2001074136A2 (en)	2000-03-31	2001-10-11	Geron Corporation	Telomerase inhibitor polynucleotides
US6342358B1 (en)	2000-08-24	2002-01-29	The Regents Of The University Of California	Human telomerase RNA elements
US7354706B2 (en) *	2003-09-09	2008-04-08	The Regents Of The University Of Colorado, A Body Corporate	Use of photopolymerization for amplification and detection of a molecular recognition event

2000
- 2000-09-08 KR KR1020027003225A patent/KR100858465B1/ko not_active Expired - Lifetime
- 2000-09-08 JP JP2001522238A patent/JP4267233B2/ja not_active Expired - Lifetime
- 2000-09-08 EP EP08075163A patent/EP1992634A1/de not_active Withdrawn
- 2000-09-08 CN CNB008127298A patent/CN1317291C/zh not_active Expired - Lifetime
- 2000-09-08 AT AT00961689T patent/ATE391134T1/de active
- 2000-09-08 DE DE60038495T patent/DE60038495T2/de not_active Expired - Lifetime
- 2000-09-08 DK DK00961689T patent/DK1210357T3/da active
- 2000-09-08 PT PT00961689T patent/PT1210357E/pt unknown
- 2000-09-08 MX MXPA02002577A patent/MXPA02002577A/es active IP Right Grant
- 2000-09-08 CA CA002382521A patent/CA2382521C/en not_active Expired - Lifetime
- 2000-09-08 ES ES00961689T patent/ES2302701T3/es not_active Expired - Lifetime
- 2000-09-08 EP EP00961689A patent/EP1210357B1/de not_active Expired - Lifetime
- 2000-09-08 KR KR1020077024593A patent/KR20070112295A/ko not_active Ceased
- 2000-09-08 WO PCT/US2000/024688 patent/WO2001018015A1/en not_active Ceased
- 2000-09-08 HK HK02108873.3A patent/HK1049339B/en not_active IP Right Cessation
- 2000-09-08 IL IL14830400A patent/IL148304A0/xx active IP Right Grant
- 2000-09-08 AU AU73609/00A patent/AU767646B2/en not_active Expired
- 2000-09-08 US US09/657,445 patent/US6608036B1/en not_active Expired - Lifetime
2002
- 2002-02-21 IL IL148304A patent/IL148304A/en unknown
2003
- 2003-06-17 US US10/463,076 patent/US6835826B2/en not_active Expired - Lifetime
- 2003-11-21 AU AU2003262453A patent/AU2003262453A1/en not_active Abandoned
2004
- 2004-10-18 US US10/967,755 patent/US7138383B2/en not_active Expired - Lifetime
2006
- 2006-10-25 US US11/586,993 patent/US20070037770A1/en not_active Abandoned
2008
- 2008-06-26 CY CY20081100672T patent/CY1108158T1/el unknown
- 2008-08-12 JP JP2008208285A patent/JP2009046483A/ja not_active Withdrawn
2014
- 2014-07-09 US US14/327,447 patent/US20140349292A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2003513887A (ja)	2003-04-15
WO2001018015A1 (en)	2001-03-15
CN1373768A (zh)	2002-10-09
EP1210357A1 (de)	2002-06-05
HK1049339A1 (en)	2003-05-09
US20050049408A1 (en)	2005-03-03
CY1108158T1 (el)	2014-02-12
IL148304A (en)	2007-10-31
EP1992634A1 (de)	2008-11-19
JP2009046483A (ja)	2009-03-05
CA2382521C (en)	2009-08-25
DE60038495D1 (de)	2008-05-15
AU7360900A (en)	2001-04-10
IL148304A0 (en)	2002-09-12
US20070037770A1 (en)	2007-02-15
EP1210357B1 (de)	2008-04-02
US6835826B2 (en)	2004-12-28
AU767646B2 (en)	2003-11-20
CA2382521A1 (en)	2001-03-15
JP4267233B2 (ja)	2009-05-27
HK1049339B (en)	2008-06-27
US20140349292A1 (en)	2014-11-27
KR100858465B1 (ko)	2008-09-16
ES2302701T3 (es)	2008-08-01
PT1210357E (pt)	2008-06-11
DK1210357T3 (da)	2008-07-21
US6608036B1 (en)	2003-08-19
US20030212032A1 (en)	2003-11-13
DE60038495T2 (de)	2009-04-09
MXPA02002577A (es)	2003-10-14
AU2003262453A1 (en)	2003-12-18
US7138383B2 (en)	2006-11-21
CN1317291C (zh)	2007-05-23
KR20070112295A (ko)	2007-11-22
KR20020092909A (ko)	2002-12-12

Legal Events

Date

Code

Title

Description

2008-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1210357

Country of ref document: EP

Publication	Publication Date	Title
ATE391134T1 (de)	2008-04-15	Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung
FI963581L (fi)	1996-11-08	Oligonukleotidi-N3'->P5'-fosforiamidaatit: synteesi ja yhdisteet; hybridisaatio ja nukleaasinsieto-ominaisuudet
ATE318900T1 (de)	2006-03-15	Ef-1-alpha transkriptionsregulatorische dna aus hamster
DE69232055D1 (de)	2001-10-18	Peptidnukleinsäuren
DK0804456T3 (da)	2002-12-02	Peptid-nukleinsyre-konjugater
DE69623057D1 (de)	2002-09-19	Rekombinatorische klonierung in vitro unter verwendung genmanipulierter rekombinationsorte
DE69528362D1 (de)	2002-10-31	Oligomere phosphoramidat- und phosphorthioamidatverbindungen
CA2223678A1 (en)	1996-10-17	Covalently linked oligonucleotide minor groove binder conjugates
DE69637256D1 (de)	2007-10-31	Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
PT92640A (pt)	1990-06-29	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules by forming a colinear triplex the synthetic oligonucleotides and methods of use
DE3675481D1 (de)	1990-12-13	Verbindungen, enthaltend eine oligonukleotide sequenz, gebunden an eine interkalierungsverbindung und an eine aktivierbare chemische verbindung, ihre synthese und verwendungen als artifizielle sequenzspezifische nuklease.
DE69636495D1 (de)	2006-10-12	Multi-tumor abweichende wachstumsgene
EP2058327A3 (de)	2010-08-25	Gene zur Kodierung von Insektenduftstoffrezeptoren und ihre Verwendung
CY1106041T1 (el)	2011-04-06	Καινοφανης συλλεκτινη
CA2382631A1 (en)	2001-03-08	Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
DE60329925D1 (de)	2009-12-17	Zusammensetzungen und verfahren zur verwendung von fmoc-derivaten bei der dna-/rna-synthese
CA2436665A1 (en)	2002-08-08	Nucleic acid derivatives
DE60230889D1 (de)	2009-03-05	Polymergeträgerte photosensibilisatoren
Lukhtanov et al.	1997	Minor groove DNA alkylation directed by major groove triplex forming oligodeoxyribonucleotides
ATE366818T1 (de)	2007-08-15	Hirse-spezifische verzwergungsgene und verfahren ihrer anwendung
Hayes	1995	Chemical probes of DNA structure in chromatin
EP0777730A4 (de)	1999-10-13	Dna-vektor für knochenspezifische genexpression
WO2001094564A3 (en)	2002-06-13	Cis-zeatin o-glcocyltransferase from zea mays
Kuduvalli	1998	Cleavage by calicheamicin (gamma) 1 (I) of DNA within the nucleosome core particle
ITRM20000077A0 (it)	2000-02-17	Metodo per aumentare l'espressione genica per geni trasfettati.